Results 61 to 70 of about 27,201 (202)

Binary and ternary inclusion complexation of lapatinib ditosylate with β-cyclodextrin: preparation, evaluation and in vitro anticancer activity

Beni-Suef University Journal of Basic and Applied Sciences, 2022
Background Lapatinib ditosylate, an efficient tyrosine kinase inhibitor for breast cancer, poses pharmacokinetic issues, hence developing its oral delivery system is troublesome.
Preeti Tanaji Mane, Balaji Sopanrao Wakure, Pravin Shridhar Wakte   +2 more
doaj   +1 more source

Lapatinib: new opportunities for management of breast cancer [PDF]

, 2010
Approximately 20% of new diagnosed breast cancers overexpress the human epidermal growth factor receptor 2 (EGFR2), also known as erythroblastic leukemia viral oncogene homolog 2 (ERBB2) protein, as a consequence of ERBB2 gene amplification, resulting in
Liao, Julia, Gallas, Michelle, Pegram, Mark, Slingerland, Joyce   +3 more
core   +1 more source

Efficacy and safety of small-molecule TKIs in neoadjuvant treatment of HER2-positive breast cancer: a systematic review and network meta-analysis

BMC Cancer
Objective This study aimed to evaluate the efficacy and safety of small-molecule TKIs in neoadjuvant treatment of HER2-positive breast cancer using a network meta-analysis approach.
Chaoyang Wang, Dong Xiao, Chao Zhai
doaj   +1 more source

Antitumor Efficacy and Mechanisms of Lapatinib in Combination with Cisplatin on Esophageal Squamous Cancer Cells

Zhongliu Fangzhi Yanjiu, 2019
Objective To evaluate the antitumor efficacy of lapatinib in combination with cisplatin on esophageal squamous cell carcinoma (ESCC) and related mechanisms.
DOU Qiaohua, GUO Xiaofang, ZHU Xiaofei, ZHANG Yueyue, YANG Fan   +4 more
doaj   +1 more source

Direct tumour–adipocyte contact / Stroma AReactive Invasion Front Area (TAC/SARIFA) predicts adverse outcome in colorectal cancer: a focused evidence synthesis and meta‐analysis

Histopathology, Volume 89, Issue 5, Page 835-848, November 2026.
TAC/SARIFA, defined by direct tumour–adipocyte contact at the invasion front, represents a reproducible, biologically meaningful H&E biomarker with consistent adverse prognostic associations in CRC. Aims Direct tumour‐adipocyte interaction at the invasion front, termed Stroma AReactive Invasion Front Areas (SARIFA), has recently emerged as a novel H&E ...
Nic G Reitsam, Bruno Märkl, Iris D Nagtegaal, Magali Svrcek   +3 more
wiley   +1 more source

Second-line lapatinib vs. trastuzumab univariate analysis.

, 2015
Second-line lapatinib vs. trastuzumab univariate analysis.
Ariel Hammerman (796648), Haim Bitterman (635246), Sari Greenberg-Dotan (174109), Rinat Yerushalmi (432619), Ilan Feldhamer (796649)   +4 more
core   +1 more source

An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway

Biology Open, 2020
In clinical practice, some breast cancer (BC) patients carry a rare ERBB2 in-frame insertion (p. Pro780_Tyr781insGlySerPro) and are resistant to anti-ERBB2 therapy.
Zi-Yan Yang, Liu Yang, Chun-Wei Xu, Xiao-Jia Wang, Lei Lei   +4 more
doaj   +1 more source

Natural Product‐Induced Ferroptosis to Overcome Therapy Resistance in Aggressive Cancers

ChemMedChem, Volume 21, Issue 20, 28 October 2026.
Natural products trigger ferroptosis through iron overload, glutathione depletion, glutathione peroxidase 4 inhibition, and reactive oxygen species accumulation, selectively targeting aggressive, and drug‐resistant cancers. Polyphenols, alkaloids and terpenoids emerge as promising multi‐target agents to overcome therapy resistance and improve future ...
Giorgio Antoniolli
wiley   +1 more source

Chemical structures of dacomitinib and lapatinib (IS).

, 2019
Chemical structures of dacomitinib and lapatinib (IS).
Haitham AlRabiah (5513648), Ali S. Abdelhameed (6555968), Mohamed W. Attwa (3233535), Adnan A. Kadi (1489780)   +3 more
core   +1 more source

Feedback Activation of STAT3 Confers Resistance of HER2-positive Breast Cancer Cells to Lapatinib

Zhongliu Fangzhi Yanjiu, 2019
Objective To explore the role of interleukin-6 (IL-6) in lapatinib-resistant HER2-positive breast cancer cells BT-474. Methods Lapatinib-resistant BT-474 (BT-474R) cells were established. Western blot was used to test P-gp expression.
HU Xiaohong, BAI Hua, DUAN Juanjuan, LEI Xiu, ZHANG Qifang   +4 more
doaj   +1 more source